N(4)-Hydroxycytidine CAS 3258-02-4 EIDD-1931 NHC High Quality
Copia cum summa puritate et stabulo Quality
Chemical Name: N(4)-Hydroxycytidine;EIDD-1931 (NHC)
CAS: 3258-02-4
Metabolitae activae Molnupiravirensis, spondens COVID-19 inhibitor
| Nomen chemicum | N(4) -Hydroxycytidine |
| Synonyma | EIDD-1931 (NHC);β-D-N4-Hydroxycytidine |
| CAS Number | 3258-02-4 |
| CATTUS Number | RF-PI309 |
| Stock Status | In Stock, Productio Ascendite usque ad chiliogrammata |
| Formulae hypotheticae | C9H13N3O6 |
| M. Pondus | 259.22 |
| Liquescens punctum | 169.0~172.0℃ |
| Solubilitas | Solutum ad 100 mM in DMSO et 50 mM in Aquae |
| Density | 1.93±0.1 g/cm3 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Alba ad Off-White pulveris |
| NMR | Congruunt Structure |
| Puritas / Analysis Methodus | >98% (HPLC) |
| Damnum in Siccatio | ≤1.0% |
| una immunditia | ≤0.50% |
| Metalla gravis | ≤20ppm |
| Test Standard | Enterprise Standard |
| Consuetudinem | Metabolitae activae Molnupiravirensis (EIDD-2801), inhibitoris COVID-19 |
sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.
N(4)-Hydroxycytidinis (EIDD-1931, β-d-N4-hydroxycytidinis, NHC, CAS 3258-02-4) metabolita activa est EIDD-2801, pollicitatio COVID-19 inhibitoris.EIDD-1931 (NHC) latum spectrum antiviralem habet contra plures coronaviros, in iis SARS-CoV-2, MERS-CoV, SARS-CoV, et globi zoonotici 2b vel 2c Bat-CoVs cum mediocris IC50 of 0.15 μM affinis, tum aucta potentia contra a coronavirus resistentia mutationes in remdesivir inhibitor nucleoside analog.Muribus infectis cum SARS-CoV vel MERS-CoV, administratio prophylactica et therapeutica Molnupiravirorum (EIDD-2801), viva voce bioavailable NHC-prodrug (β-D-N4-hydroxycytidine-5'-isopropyl ester), munus pulmonis emendavit. virum titer et pondus corporis iacturam redegit.MERS-CoV decrescentes cedit in vitro et in vivo associati sunt auctae mutationis frequentiae transitus in virales sed non in cellula RNA hospes, mechanismum muta- tionis letalis in CoV sustinens.Potentia NHC/EIDD-2801 contra plures coronaviros et bioavailability oralis auget suam utilitatem potentialem sicut antiviralem efficacem contra SARS-CoV-2 et alios coronaviros zoonoticos futuros.
